EGFR+ Lung Cancer | Clinical

China’s NMPA to Review NDA of Zorifertinib for EGFR-Mutated NSCLC With CNS Metastases

January 30, 2023

The phase 2/3 EVEREST study of zorifertinib for patients with advanced EGFR-mutated non–small cell lung cancer with central nervous system metastases elicited significant efficacy and comparable safety to other tyrosine kinase inhibitors in this indication.

FDA Accepts IND for HT-001 for EGFRi-Associated Rash and Skin Disorders

January 17, 2023

Based on the acceptance of its investigational new drug application by the FDA, the safety and tolerability of HT-001 will be evaluated in the phase 2a CLEER of patients with rash and skin disorders associated with EGFR inhibitor therapy.

Piotrowska Looks at Amivantamab and Mobocertinib for Patients With Rare Driver Mutations in NSCLC

January 16, 2023

During a Targeted Oncology case-based roundtable event, Zofia Piotrowska, MD, MHS, discussed molecular testing for actionable mutations and recommended treatments for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.

Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC

December 05, 2022

During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.

Nadler Reviews Targeted Therapy for EGFR Exon 20 Insertion NSCLC

November 21, 2022

During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.